Clinical Trials Browser

Interventional × Has announcements × lenvatinib × Clear all

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

827 enrolled 34 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Neoplasms

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms